The measuring, meaning and importance of activities of daily living (ADLs) as an outcome

International Psychogeriatrics

Volumn 19, Issue 3, 2007, Pages 467-482

  Rockwood, Kenneth ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Centre for Health Care of the Elderly   (Canada)

Author keywords

Alzheimer's disease; Clinical trials; Dementia; Disability; Function

Indexed keywords

COGNITIVE DEFECT; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DEMENTIA; DISABILITY; FAMILY; FUNCTIONAL ASSESSMENT; HUMAN; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; LEISURE; OUTCOMES RESEARCH; PHYSICIAN; RATING SCALE; TASK PERFORMANCE;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; CLINICAL TRIALS; DISABILITY EVALUATION; DISEASE PROGRESSION; GERIATRIC ASSESSMENT; HUMANS; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); SENSITIVITY AND SPECIFICITY;

EID: 34248170832     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610207004966     Document Type: Conference Paper

References (64)

1. Albert, S. M., Bear-Lehman, J., Burkhardt, A., Merete-Roa, B., Noboa-Lemonier, R. and Teresi, J. (2006). Variation in sources of clinician-rated and self-rated instrumental activities of daily living disability. Journal of Gerontology Series A: Biological Sciences and Medical Sciences, 61, 826-831.
2. American Psychiatric Association (APA) (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: APA.
3. Behl, P., Lanctot, K. L., Streiner, D. L., Guimont, I. and Black, S. E. (2006). Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort. Current Alzheimer Research, 3, 147-156.
4. Black, S. et al.; Donepezil 307 Vascular Dementia Study Group (2003). Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 34, 2323-2332.
5. Bray, K., Fisher, A. G. andDuran, L. (2001). The validity of adding new tasks to the assessment of motor and process skills. American Journal of Occupational Therapy, 55, 409-415.
6. Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, NJ: LEA.
7. Craig, D. and Birks, J. (2006). Galantamine for vascular cognitive impairment. Cochrane Database System Review, 25 (1), CD004746.
8. DeJong, R., Osterlund, O. W. and Roy, G. W. (1989). Measurement of quality-of-life changes in patients with Alzheimer's disease. Clinical Therapeutics, 11, 545-554.
9. Doble, S. E., Fisk, J. D. and Rockwood, K. (1999). Assessing the ADL functioning of persons with Alzheimer's disease: comparison of family informants' ratings and performance-based assessment findings. International Psychogeriatrics, 11, 399-409.
10. Doody, R., Wirth, Y., Schmitt, F. and Mobius, H. J. (2004). Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 18, 227-232.
11. Emre, M. et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509-2518.
12. Erkinjuntti, T., Kurz, A., Small, G. W., Bullock, R., Lilienfeld, S. and Damaraju, C. V.; GAL-INT-6 Study Group (2003). An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clinical Therapeutics, 25, 1765-1782.
13. Feldman, H., Schulzer, M., Wang, S., Tuokko, H. and Beattie, B. L. (1995). The Functional Rating Scale in Alzheimer's disease assessment: a longitudinal study. In K. Iqbal, J. A. Mortimer, B. Winblad and H. M. Wisniewski (eds.). Research Advances in Alzheimer's Disease and Related Disorders (pp. 235-241). Chichester: Wiley.
14. Feldman, H. et al. (2001a). The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Disease and Associated Disorders, 15, 89-95.
15. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P. and Whalen, E.; Donepezil MSAD Study Investigators Group (2001b). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620.
16. Feldman, H., Van Baelen, B., Kavanagh, S. M. and Torfs, K. E. (2005). Cognition, function and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders, 19, 29-36.
17. Galasko, D. et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S33-S39.
18. Galasko, D., Schmitt, F., Thomas, R., Jin, S. and Bennett, D.; Alzheimer's Disease Cooperative Study (2005). Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychological Society, 11, 446-453.
19. Gauthier, S., Gelinas, I. and Gauthier, L. (1997). Functional disability in Alzheimer's disease. International Psychogeriatrics, 9 (Suppl. 1), 163-165.
20. Gélinas, I., Gauthier, L., McIntyre, M. and Gauthier, S. (1999). Development of a fundamental measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy, 53, 471-481.
21. Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H-P. and Van Den Bussche, H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ, 331, 321-327.
22. Kiresuk, T. J. and Sherman, R. E. (1968). Goal Attainment Scaling: a general method for evaluating comprehensive community health programs. Community Mental Health Journal, 4, 443-453.
23. Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9, 179-186.
24. Leber, P. D. (1997a). Developing safe and effective antidementia drugs. In R. Becker and E. Giacobini (eds.), Alzheimer Disease: from Molecular Biology to Therapy (pp. 579-584). Boston: Birkhauser.
25. Leber, P. D. (1997b). Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Disease and Associated Disorders, 11 (Suppl. 5), S10-S21, discussion S37-S39.
26. Liang, M. H., Fossel, A. H. and Larson, M. G. (1990). Comparisons of five health status instruments for orthopedic evaluation. Medical Care, 28, 632-642.
27. Maidment, I., Fox, C. and Boustani, M. (2006). Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database System Review, 25 (1), CD004747.
28. McDowell, I. (2006). Measuring Health, 3rd edition. Oxford: Oxford University Press.
29. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Human Services Task Force on Alzheimer's disease. Neurology, 34, 939-944.
30. Mitnitski, A., Dai, D. W. and Rockwood, K., for the GAL-INT-13 Investigators (2005). Modeling decline in Alzheimer's disease: a linear model (the Stern equation) compared with a logistic function. International Psychogeriatrics, 17 (Suppl. 2), 203-204.
31. Mohs, R. C. et al. (2001). A 1-year placebo controlled preservation of function survival study of donepezil in Alzheimer disease patients. Neurology, 57, 481-488.
32. Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412-2414.
33. Muresanu, D. F., Rainer, M., and Moessler, H. (2002). Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. Journal of Neural Transmission Supplementum, 62, 277-285.
34. Peskind, E. R. et al. (2006). Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. American Journal of Geriatric Psychiatry, 1, 704-715.
35. Pirttila, T., Wilcock, G., Truyen, L. and Damaraju, C. V. (2004). Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European Journal of Neurology, 11, 734-741.
36. Potkin, S. G. (2002). The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Inernational Psychogeriatrics, 14 (Suppl 1), 7-26.
37. Quinn, J. et al. (2002). A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology, 58, 433-437.
38. Ramirez Diaz, S. P. et al. (2005). The need for a consensus in the use of assessment tools for Alzheimer's disease: the feasibility study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey. International Journal of Geriatric Psychiatry, 20, 744-748.
39. Raskind, M. A., Peskind, E. R., Wessel, T. and Yuan, W.; the Galantamine USA-1 Study Group (2000). Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology, 54, 2261-2268.
40. Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. and Damaraju, C. V. (2004). The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurology, 61, 252-256.
41. Reisberg, B. (1988). Functional Assessment Staging (FAST). Psychopharmacology Bulletin, 24, 653-659.
42. Reisberg, B., and Ferris, S. H. (1988). Brief Cognitive Rating Scale (BCRS). Psychopharmacology Bulletin, 24, 629-636.
43. Reisberg, B., Ferris, S. H., de Leon, M. J. and Crook, T. (1982). The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry, 139, 1136-1139.
44. Reisberg, B. et al. (2001). The Alzheimer's disease activities of daily living international scale (ADL-IS). International Psychogeriatrics, 13, 163-181.
45. Rockwood, K. (2004). Size of the treatment effect on the cognition of cholinesterase inhibition in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 75, 677-685. Erratum in Journal of Neurology, Neurosurgery and Psychiatry, 75, 1086.
46. Rockwood, K. and Joffres, C. (2002). Halifax Consensus Conference on Understanding the Effects of Dementia Treatment. Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations. International Journal of Geriatric Psychiatry, 17, 1006-1011.
47. Rockwood, K., Mintzer, J., Truyen, L., Wessell, T. and Wilkinson, D. (2001). Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 71, 589-595.
48. Rockwood, K., Wallack, M. and Tallis, R. (2003). The treatment of Alzheimer's disease: success short of cure. Lancet Neurology, 2, 630-633.
49. Rockwood, K., Fay, S., Song, X., MacKnight, C. and Gorman, M., on behalf of the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators (2006a). Attainment of goals in patients treated with galantamine: a randomized, controlled trial. Canadian Medical Association Journal, 174, 1099-1105.
50. Rockwood, K., Fay, S. and Gorman, M., on behalf of the VISTA Study Investigators (2006b). The ADAS-Cog and the detection of clinically important improvements in Alzheimer's disease patients treated with galantamine. Alzheimer's and Dementia, 2 (Suppl 3), S371.
51. Rosen, W. G., Mohs, R. C. and Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356-1364.
52. Rösler, M. et al., on behalf of the B303 Rivastigmine Study Group (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ, 318, 633-638.
53. Rustembegovic, A., Kundurovic, Z., Sapcanin, A. and Sofic, E. (2003). A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. Medicinski Arhiv, 57, 149-150.
54. Sparks, D. L. et al. (2005). Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Current Alzheimer Research, 2, 343-353.
55. Stern, R. G. et al. (1994). A longitudinal study of Alzheimer's disease. American Journal of Psychiatry, 151, 390-396.
56. Suh, G. H. et al. (2004). A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clinical Therapeutics, 26, 1608-1618.
57. Tariot, P. N. et al. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
58. Tariot, P. N. et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society, 49, 1590-1599.
59. Thomas, V. S., Rockwood, K. and McDowell, I. (1998). Multidimensionality in instrumental and basic activities of daily living. Journal of Clinical Epidemiology, 51, 315-321.
60. Üstün, T., B., Chatterji, S., Bickenbach, J., Kostanjsek, N. and Schneider, M. (2003). The International Classification of Functioning, Disability and Health: a new tool for understanding disability and health. Disability and Rehabilitation, 25, 565-571. DOI: 10.1080/ 0963828031000137063.
61. Wilcock, G. K., Lilienfeld, S. and Gaens, E. (2000). Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre, randomised controlled trial. BMJ, 321, 1445-1449. Erratum in BMJ (2001), 322, 405.
62. Wilkinson, D. G. et al. (2002). A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice, 56, 441-446.
63. Winblad, B. et al. (2006). Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367, 1057-1065.
64. World Health Organization (1980). International Classification of Impairments Disabilities and Handicaps: A Manual of Classification Relating to the Consequences of Disease. Geneva: WHO.